AGP Executive Report
Last update: 10 hours agoObesity drug dealmaking: Novo Nordisk agreed to license Hengrui’s once-weekly oral GLP-1/GIP dual agonist HRS-1596 in a deal worth up to US$2.6 billion (US$300m upfront), with development and sales milestones and royalties; the therapy is aimed at obesity and metabolic disease, and is not yet tested in people. Muscle-sparing weight-loss research: Regeneron reported Phase 2 COURAGE trial results showing trevogrumab helped prevent lean mass and muscle loss during semaglutide-induced weight loss, with plans to study the approach in older adults with obesity and low muscle mass/strength. Local health & safety in Macau: The Public Security Police Force reported a fatal motorcycle crash on the Macau-Taipa Friendship Bridge, while another incident saw a rider injured after a taxi failed to give way. Youth wellbeing and school safety: A Macau lawmaker urged stronger early prevention and psychological counselling after separate cases of student violence involving corrosive liquid and a stabbing. Community health support: Macau’s Municipal Affairs Bureau said 523 stray dogs and cats were adopted last year and highlighted ongoing quarantine and adoption-focused management.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[Pharmaceutical Executive Daily: CSL & Alentis Enter $1.6 Billion Global Partnership]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/24990778-912932933-69ad66ff9a88b963b53a43ee2436f89da07d52ad-1280x720-100x56.jpeg)
